ACP-204
Total Payments
$2.7M
Transactions
593
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.7M | 593 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.7M | 592 | 99.9% |
| Consulting Fee | $1,500 | 1 | 0.1% |
Payments by Type
Research
$2.7M
592 transactions
General
$1,500
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ACP-204-006 | ACADIA Pharmaceuticals Inc | $2.2M | 0 |
| ACP-204-008 | ACADIA Pharmaceuticals Inc | $458,832 | 0 |
Top Doctors Receiving Payments for ACP-204
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miami, FL | $2.7M | 592 |
| , M.D | Nephrology | San Francisco, CA | $1,500 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.7M
- Total Doctors 1
- Transactions 593
About ACP-204
ACP-204 is a drug associated with $2.7M in payments to 1 healthcare providers, recorded across 593 transactions in the CMS Open Payments database. The primary manufacturer is ACADIA Pharmaceuticals Inc.
Payment data is available from 2024 to 2024. In 2024, $2.7M was paid across 593 transactions to 1 doctors.
The most common payment nature for ACP-204 is "Unspecified" ($2.7M, 99.9% of total).
ACP-204 is associated with 2 research studies, including "ACP-204-006" ($2.2M).